No Data
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Beijing Sl Pharmaceutical (002038.SZ): Obtained the Pharmaceutical registration certificate for Telmisartan Amlodipine Tablets (II).
On March 14, Glonghui reported that Beijing Sl Pharmaceutical (002038.SZ) announced that it recently received the Drug Registration Certificate approved by the National Medical Products Administration for Telmisartan and Amlodipine Tablets (II) (Trade Name: Lifengyuan). Telmisartan and Amlodipine Tablets (II) is a compound preparation consisting of Telmisartan and Amlodipine. Telmisartan is an angiotensin II receptor antagonist that lowers blood pressure by blocking the effects of angiotensin II; Amlodipine is a calcium channel blocker that primarily lowers blood pressure by inhibiting the entry of calcium ions into heart and smooth muscle cells. The combination of Telmisartan and Amlodipine can
Shuanglu Pharmaceutical: Beijing Shuanglu Pharmaceutical Co., Ltd. 2024 Annual Results Forecast
Beijing SL Pharmaceutical (002038.SZ) has obtained the registration certificate for the pharmaceutical of desloratadine tablets.
Beijing SL Pharmaceutical (002038.SZ) announced that the company recently received the State Food and Drug Administration (referred to as the "National Drug...
Beijing SL Pharmaceutical (002038.SZ): Key products that have entered the national centralized procurement include the pharmaceuticals Temozolomide, Lenalidomide, and Ornidazole.
Gelonghui, November 13, 丨 Shuanglu Pharmaceutical (002038.SZ) said on November 12, 2024, that the company's key products that have entered national collection include temozolomide, lenalidomide, and ornidazole. Drugs that have entered interprovincial alliances and local collection include recombinant human granulocyte stimulating factor injections, thymus pentapeptides, interleukin-2, interleukin-11, and cyclosporine. Currently, most of the company's main varieties may have been included in the collection. Large and newly approved products , the company will replace it with the price
Beijing SL Pharmaceutical (002038.SZ): It is expected that next year's significant stock price fluctuations will not have a negative impact on the company.
On November 13th, Ge Longhui reported that Beijing SL Pharmaceutical (002038.SZ) stated during a specific object survey on November 12, 2024, that the situation is expected to improve next year. In the future, the company will participate in the national centralized procurement of most new varieties listed in the past one or two years, and will not be negatively impacted by significant price reductions. It may become a new source of growth. The company's financial assets are currently at relatively low levels, and it is expected that next year's significant fluctuations in stock prices will not adversely affect the company.